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ABSTRACT: In this study, Taguchi design was used to determine optimal parameters for the preparation of bovine serum albumin
(BSA)-loaded nanoparticles (NPs) using a biodegradable polymer poly(glycerol adipate-co-ω-pentadecalactone) (PGA-co-PDL). NPs were
prepared, using BSA as a model protein, by the double emulsion evaporation process followed by spray-drying from leucine to form
nanocomposite microparticles (NCMPs). The effect of various parameters on NP size and BSA loading were investigated and dendritic cell
(DC) uptake and toxicity. NCMPs were examined for their morphology, yield, aerosolisation, in vitro release behaviour and BSA structure.
NP size was mainly affected by the polymer mass used and a small particle size ≤500 nm was achieved. High BSA (43.67 ± 2.3 µg/mg)
loading was influenced by BSA concentration. The spray-drying process produced NCMPs (50% yield) with a porous corrugated surface,
aerodynamic diameter 1.46 ± 141 µm, fine particle dose 45.0 ± 4.7 µg and fine particle fraction 78.57 ± 0.1%, and a cumulative BSA
release of 38.77 ± 3.0% after 48 h. The primary and secondary structures were maintained as shown by sodium dodecyl sulphate poly
(acrylamide) gel electrophoresis and circular dichroism. Effective uptake of NPs was seen in DCs with >85% cell viability at 5 mg/mL
concentration after 4 h. These results indicate the optimal process parameters for the preparation of protein-loaded PGA-co-PDL NCMPs
suitable for inhalation. C© 2015 Wiley Periodicals, Inc. and the American Pharmacists Association J Pharm Sci
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INTRODUCTION
Pharmaceutical research has recently focussed on developing
delivery systems for macromolecules such as proteins, peptides
and antigens as they become the preferred therapeutics be-
cause of their greater selectivity, lower disruption of normal bi-
ological processes and reduced clinical development time with a
shorter United States Food and Drug Administration approval
period.1 However, to reach a therapeutic level most of these
macromolecules must be administered repeatedly in an inva-
sive manner.2 The pulmonary delivery of macromolecules is a
viable alternative because of the attractive physiological prop-
erties of the lungs; the pulmonary epithelium is more perme-
able and lower enzymatic activity than the gut. In addition, it
Abbreviations used:: BCA, bicinchoninic acid; BSA, bovine serum albumin;
CLSM, confocal laser scanning microscopy; CD, circular dichroism; DMSO,
dimethyl sulfoxide; DCM, dichloromethane; DCs, dendritic cells; DL, drug
loading; DPIs, dry powder inhalers; EAP, external aqueous phase; FITC, flu-
orescein isothiocyanate; FPD, fine particle dose; FPF%, fine particle fraction
percentage; HDL, high drug loading; IAP, internal aqueous phase; MTT, 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; MEM, minimum essen-
tial medium; MMAD, mass median aerodynamic diameter; NCMPs, nanocom-
posite microparticles; NGI, next-generation impactor; NPs, nanoparticles; OP,
organic phase; PBS, phosphate buffer saline; PGA-co-PDL, poly(glycerol adipate-
co-T-pentadecalactone); PLGA, poly(lactic-co-glycolic acid); PVA, poly(vinyl alco-
hol); SDS-PAGE, sodium dodecyl sulphate poly(acrylamide) gel electrophoresis;
S/N, single-to-noise ratio; SPS, smaller particle size; SEM, scanning electron
microscopy; TGA, thermogravimetric analysis; w/o/w, water-in-oil-in-water.
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has a large surface area that is highly vascularised with thin
epithelium in the alveolar lung tissue.3 In addition, the pul-
monary epithelium has many immunological properties.2 Most
organisms causing respiratory infections attack the host via
the mucosal membrane. Consequently, the non-invasive pul-
monary delivery of antigens can provide protection to mucosal
membranes at the site of infection and potentially provides
a first-line defense against invading microorganism.4 The ex-
tensive dendritic cell (DC) networks that line the respiratory
epithelium are considered an ideal target to initiate a strong
immune response.2 Moreover, pulmonary delivery reduces the
risk of cross contamination due to the reuse of needles and sy-
ringes, and eliminates needle stick injuries, in both patients
and medical personnel.4
Nanoparticles (NPs) are a useful delivery system for pul-
monary macromolecules because of their potential for target-
ted drug delivery, sustained release and reduced dosing fre-
quency, hence improving patient compliance and convenience.5
They provide an additional advantage for antigen delivery
systems, with studies suggesting NPs of about 500 nm or
less were optimal for DCs uptake.6,7 A most common method
for the encapsulation of water-soluble drugs such as pro-
tein, peptides and antigens in biodegradable polymer-based
NPs is the water-oil-water (w/o/w) double-emulsion solvent
evaporation method.2 Biodegradable poly(glycerol adipate-co-
T-pentadecalactone, PGA-co-PDL) has previously been inves-
tigated as a novel delivery system of small molecule, for ex-
ample, dexamethasone phosphate,8 model drugs, for example,
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ibuprofen9 and sodium fluorescein,10 and macromolecules, for
example, DNase I,11 via dry powder inhalation (DPIs). However,
particles smaller than 1 :m show poor lung deposition and are
likely to be exhaled because of their low inertia, whereas parti-
cles larger than 5 :m cannot pass the oropharynx effectively.12
Hence, to achieve particle deposition in the respirable region of
the lung, the particles should be in the size range 1–5 :m. NPs
can be formulated into microparticle carriers with an aerody-
namic diameter between 1 and 5 :m to form nanocomposite
microparticles (NCMPs) as DPIs by spray-drying.13–16
Spray-drying is a process where the formulation is presented
as a feed solution, suspension or emulsion and converted into
fine droplets, followed by exposure to rapid hot air-stream re-
sulting in dry respirable-sized powders. In addition to the com-
position of the feed formulation, several operational parame-
ters greatly affect the quality and quantity of the final formula-
tion such as inlet temperature, air flow, aspiration capacity and
feed rate.17–20 Biocompatible excipients (carbohydrates, amino
acids and lipids) are typically added to the formulation feed to
afford dry powders with bulk and to promote the production
of a desirable aerodynamic particle size which upon inhala-
tion allows rapid release of NPs in the lung fluid.10,13,17,21–23
In addition, the excipients can protect the NPs and encapsu-
lated agents against the extreme spray-drying process condi-
tions such as high temperatures and shear forces.24 Delivering
these microparticle carriers as DPIs via the pulmonary route
offer many advantages such as not requiring trained medical
personnel, eliminates cold-chain requirements and offers in-
creased physical and chemical stability of macromolecules in
comparison with liquid formulations.4
The Taguchi design is a useful method for studying a large
number of parameters and interactions as it has the ability to
optimise many parameters simultaneously and extract quanti-
tative data from only a few experiments compared with the
traditional factorial design.25,26 For example, a single repli-
cate of four parameters and three level experiments would re-
quire 81 runs for a full factorial analysis. However, using the
Taguchi method will require only nine runs. The Taguchi ap-
proach has previously been used in the improvement of dosage
forms.25 Moreover, the Taguchi design concentrates on product
robustness against uncontrollable (noise) factors. It employs a
signal-to-noise (S/N) ratio to quantify variations. These ratios
are meant to be used as measures of the effect of noise (un-
controllable) factors on performance characteristics. S/N ratios
take into account both amount of variability in response data
and closeness of average response to the target (1). In Taguchi
design, S/N ratio can be defined as the measure of the deviation
of the response from the desired value. So, ‘signal’ presents the
mean value and ‘noise’ presents the SD. It means that lower
variability in the process is ensured through maximising the
S/N ratio (2). The variability of a characteristic is due to the
noise factor such as environmental factors. Thus, optimising
process parameters by the Taguchi design leads to bringing the
average quality near to the target value, and also to simulta-
neously decrease the variation in quality (3). The experimental
condition having the maximum S/N ratio is considered the opti-
mum condition, as the variability of characteristics is in inverse
proportion to the S/N ratio (4).
In this study, we have formulated PGA-co-PDL NPs encap-
sulating bovine serum albumin (BSA), a model protein, using
Taguchi design to optimise NPs size and drug loading (DL)
for effective uptake by DCs. The PGA-co-PDL NPs were then
incorporated into L-leucine microparticle carriers via spray-
drying using condition optimised using Taguchi design to pro-
duce NCMPs carriers suitable for pulmonary delivery via DPIs,
maintaining BSA structure and activity.
MATERIALS AND METHODS
Materials Q1
Poly(glycerol adipate-co-T-pentadecalactone) (MW of 16.7 kDa)
polymer was synthesised and characterised in our laboratory
as previously described by Thompson et al.27 BSA was obtained
from (MW 67 kDa) Avenchem, UK. Poly(vinyl alcohol) (PVA;
MW of 13–23 kDa, 87%–89% hydrolysed) was obtained from
Clariant GmbH, Frankfurt, Germany. Dichloromethane (DCM)
was purchased fromBDH, Laboratory Supplies, UK. QuantiPro Q2
bicinchoninic acid (BCA) protein assay kit, L-leucine, phosphate
buffer saline tablet (PBS; pH 7.4), 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide (MTT), RPMI-1640 medium
with L-glutamine and sodium hydrogen carbonate (NaHCO3),
tween 80, albumin tagged with fluorescein isothiocyanate
(FITC-BSA) were purchased from Sigma–Aldrich, UK. Min-
imum essential medium (MEM) alpha-nucleosides were ob-
tained from Gibco by Life Technologies, UK. 75 cm2/tissue cul-
ture flask (vented cap), 96-well flat bottom plates, acetone, an-
tibiotic/antimyotic solution (100×), dimethyl sulfoxide (DMSO)
and paraformaldehyde were purchased from Fisher Scientific,
UK. CVS10D omniPAGE vertical gel electrophoresis system,
protoGel stacking buffer, protein molecular weight markers
in the range 10–220 kDa, protein loading buffer blue (2×)
[0.5 M Tris–HCl (pH 6.8), 4.4% (w/v) SDS, 20% (v/v) glyc-
erol, 2% (v/v) 2-mercaptoethanol and bromphenol blue in dis-
tilled/deionised water], Tris–glycine–sodium dodecyl sulphate-
polyacrylamide gel electrophoresis (SDS-PAGE) buffer (10×)
containing 0.25 M Tris base, 1.92 M glycine and 1% (w/v) SDS
were purchased from Geneflow Limited, UK. 4-Nitrophenyl ac-
etate esterase substrate (NPAES) was purchased from Sigma–
Aldrich. Heat inactivated foetal calf serum (FCS) was pur-
chased from Biosera, UK. Adenocarcinomic human alveolar
basal epithelial cell line, A 549 (CCL-185TM) and immature
DCs; monocyte, mouse, JAWS II (CRL-11904TM) were pur-
chased from American Type Culture Collection (ATCC); 4′,6-
diamidino-2-phenylindole, dihydrochloride (DAPI) and Wheat
Germ Agglutinin Texas RedR-X conjugate (WGA TR) were pur-
chased from Invitrogen, Ltd., UK.
Experimental Design and NP Preparation
Taguchi design L36 orthogonal array was constructed through
Minitab 16 Statistical Software R© (Minitab Inc., Pennsylvania).
It was composed of eight variables set at two levels or three
levels (Table 1). This design was used to identify the important
parameters that would influence the NP size and BSA load-
ing. A high signal-to-noise (S/N) ratio indicated the optimum
conditions. The signal factor (S) was the outcome, that is, par-
ticle size or BSA loading and noise factors (N) included room
temperature, humidity, experience of researcher and so on. Op-
timisation of the particle size and BSA loading was performed
using the Taguchi’s ‘smaller-is-better’ and ‘larger-is-better’ cri-
terion, respectively.28
Bovine serum albumin-loaded PGA-co-PDL NPs were pre-
pared using a (w/o/w) double emulsion/solvent evaporation
method. Briefly, BSA solution containing PVA (internal aque-
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Table 1. Double Emulsion Solvent Evaporation Processing Variables, Units and Levels for BSA-Loaded PGA-co-PDL NPs
Code Variables Unit Levels
1 2 3
A IAP volume mL 0.25 0.5 –
B OP volume mL 1 2 –
C BSA concentration % 50 100 200
D Polymer mass mg 50 100 200
E PVA concentration % 1 5 10
F Sonication time IAP s 5 10 15
G Sonication time EAP s 10 15 30
H Sonication amplitude % 30 45 65
IAP, internal aqueous phase; OP, organic phase; EAP, external aqueous phase.
ous phase, IAP) was emulsified in DCM (organic phase, OP)
containing PGA-co-PDL, using a probe sonicator (VC X 500
Vibra-CellTM; Sonics & Materials, Inc., Newtown, Connecticut;
13 mm probe) over an ice bath. The resulting single emulsion
was emulsified into 25 mL of a PVA solution (1%, w/v) (ex-
ternal aqueous phase, EAP) using the same probe sonicator
to form a w/o/w double emulsion. The DCM was evaporated
by magnetically stirring the double emulsion for 2 h at room
temperature. The NPs were collected by centrifugation (Sigma
3–30k; SIGMA Laborzentrifugen GmbH, Germany) at 40,000g
for 1 h at 4◦C, and washed twice with distilled water. Control
NPs were prepared using the same method without BSA.
Experimental Design and NCMPs Preparation
A second design was constructed using an L27 orthogonal array
design throughMinitab 16 Statistical Software R© (Minitab Inc.).
It composed of five variables each set at three levels (Table 2).
Optimisation of yield% was undertaken using the Taguchi’s
‘larger-is-better’ criterion.
Spray-drying was used to incorporate the PGA-co-PDL NPs
into NCMPs using L-leucine as a carrier. NPs (control and BSA
loaded) were suspended in an aqueous L-leucine solution at a
polymer-to-carrier ratio of 1:1.5 (w/w) and spray-dried with a
Bu¨chi B-290 mini-spray dryer (Bu¨chi Labortechnik, Switzer-
land) containing a standard two-fluid nozzle (0.7 mm diam-
eter). The dried powder (PGA-co-PDL/L-leucine NCMPs) was
separated from the air stream using a high-performance cy-
clone (Bu¨chi Labortechnik), collected and stored in a desiccator
at room temperature prior to further investigations.
NP Characterisation
Particle Size, Polydispersity Index and Zeta Potential.
Samples were analysed by laser diffraction (Zetasizer Nano
ZS; Malvern Instruments Ltd., UK). Briefly, 200 :L aliquot of
the double emulsion sample was diluted with deionised water
(8 mL), and placed into a cuvette with the measurements con-
ducted at ambient temperature (25◦C) (n = 3).
Protein Loading of NPs.
The amount of protein loaded in the NPs was determined by
measuring the amount of protein remaining in the supernatant
and wash after centrifugation using a QuantiPro BCA protein
assay kit (n = 3), by UV spectroscopy at 562 nm (Genesys 5
spectrophotometer; Thermo Fisher Scientific Inc., Waltham,
Massachusetts). A calibration curve was obtained with BSA
standard solutions (2.5–30 :g/mL) and the DL was calculated
according to Eq. 1:
DL =
actual amount of encapsulatedBSA (:g)
actual amount of nanoparticles (mg)
(1)
NCMPs Characterisation
Particle Size and Morphology.
To ensure the recovery of NPs from NCMPs, 5 mg of NCMPs
was suspended in 10 mL deionised water and measurements
performed as described in section 1.5.1 (n = 3). Q3
Scanning electron microscopy (SEM) (FEI—QuantaTM 200
ESEM, Holland) was used to visualise the morphology of
NCMPs. Spray-dried NCMPs samples were placed on alu-
minium stubs (pin stubs, 13 mm) covered with a conductive
carbon tab and coated (EmiTech K 550X Gold Sputter Coater,
25 mA) with palladium (10–15 nm) for 3 min.
Yield of Spray-Dried NCMPs.
The percentage yield of dry powder NCMPs was calculated as
the mass of expected total powder (n = 3) according to Eq. 2:
%Yeild =
Weight of powder collected after spray drying
Weight of total dry mass used for the preparation
× 100(2)
Moisture Content.
Thermogravimetric analysis (TGA Q50, UK equipped with TA
universal analysis 2000 software) was used to evaluate the
moisture content of dry powder NCMPs after spray-drying. Ap-
proximately 10–15 mg of NCMPs was placed in a platinum
pan and heated between 25◦C and 650◦C at a purged with ni-
trogen at 20 mL/min and a scanning rate at 10◦C/min. The
moisture content was analysed for data collected between 25◦C
and 120◦C.
Powder Density and Primary Aerodynamic Diameter.
The tapped density of selected NCMPs was determined by in-
serting approximately 0.2 g of powder into a 5 mL graduated
cylinder and recording the initial volume. Tapped density mea-
surements were then performed until no change in volume was
observed (n= 3). The data obtained from geometric particle size
(d) and tapped density (D) was used to determine the theoretical
aerodynamic diameter (dae) according to Eq. 3.
dae = d
√
D
D1 D1=1 g/cm3
(3)
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Table 2. Spray-Drying Processing Variables, Units and Levels for BSA-Loaded PGA-co-PDL NCMPs
Code Variable Unit Level
1 2 3
A Air flow L/h 400 535 670
B Inlet temp C 50 75 100
C Aspirator % 50 75 100
D Feed rate % 5 10 15
E Concentration mg/mL 12.5 6.25 4.17
In Vitro Aerosolisation Investigations.
The aerosolisation studies of the NCMPs were evaluated using
the next-generation impactor (NGI). Optimum NCMPs formu-
lations (n = 3) were filled into capsules (hydroxypropyl methyl-
cellulose, size 3. 4 capsules each corresponding to 10 mg spray-
dried powder) and aerosolised via a Cyclohaler R© (Teva Pharma)
into NGI. The capsules were punctured using the actuator of
the Cyclohaler R© prior to inhalation at a flow rate of 60 L/min for
4 s.29 The samples were collected using DCM/0.15 M NaCl mix-
ture (2:1) to extract the BSA from the polymer, which was then
analysed by the QuantiPro BCA protein assay as mentioned
above. The fine particle dose (FPD) was determined as the to-
tal mass of powder deposited in NGI stages with aerodynamic
diameters less than 4.5 :m, the fine particle fraction (FPF%)
was determined as the fraction of emitted dose deposited in the
NGI with aerodynamic diameters less than 4.5 :m, and the
mass median aerodynamic diameter (MMAD) was calculated
from log-probability analysis.
In Vitro Release Studies.
Nanocomposite microparticles samples (10 mg) were placed in
microtubes and dispersed in 1.2 mL of PBS (pH 7.4), and in-
cubated at 37◦C, rotating at 20 RPM in a sample mixer (Hu-
laMixer, Invitrogen Dynal AS, Life Technologies). At predeter-
mined time intervals up to 48 h, samples were centrifuged
(13,000 rpm for 30 min) and 0.5 mL of the supernatant re-Q4
moved and replaced with fresh buffer. The supernatant was
analysed by QuantiPro BCA protein assay as mentioned above
(n = 3). The percentage cumulative BSA released was calcu-
lated according to Eq. 4.
%Cumulative protein released
=
cumulative protein released
actual protein loaded
× 100 (4)
The% cumulative protein release was assessed using zero or-
der, first order and Higuchi’s square root plot release models.30
The correlation coefficient was calculated from the following
graphical representations, zero order: % cumulative protein re-
lease versus time; first order: log% cumulative protein remain-
ing versus time; Higuchi: % cumulative protein release versus
square root of time.
Protein Characterisation
Sodium Dodecyl Sulphate-Polyacrylamide Gel Electrophoresis.
The primary structure of released BSA from NPs and NCMPs
was characterised by SDS-PAGE performed on a CVS10D om-
niPAGE vertical gel electrophoresis system with 9% stacking
gel prepared using ProtoGel stacking buffer containing 0.4%
of SDS. Protein samples and standard were treated with pro-
tein loading buffer blue (2×) (0.5 M Tris–HCl (pH 6.8), 4.4%
(w/v) SDS, 20% (v/ v) glycerol, 2% (v/v) 2-mercaptoethanol and
bromphenol blue in distilled/deionised water) in a ratio 1:1
(v/v) buffer-to-sample for 3 min at 95◦C. The protein molec-
ular weight marker, standard and samples were loaded into
the wells (25 :L per well). Electrophoresis was performed with
Tris–glycine–SDS-PAGE buffer (10×) [0.25MTris base, 1.92M
glycine, 1% (w/v) SDS] at a constant voltage of 100 V for 2.3 h.
Coomassie Brilliant Blue was used to stain the gel followed
by destaining in distilled water for 24 h. Gel scanner (GS-700
Imaging Densitometer; Bio-Rad) equipped with Quantity One
software was used for the gel imaging and documentation.
Circular Dichroism.
The secondary structure of standard BSA (as a control), and
BSA released after 48 h from NCMPs in PBS was determined
via circular dichroism (CD) using a J-815 spectropolarimeter
(Jasco, UK) at 20◦C as reported previously.31 Five scans were
recorded per sample using a 10 mm path-length cells at far-
UV wavelengths from 260 to 180 nm at a data pitch of 0.5 nm,
band width of 1 nm and a scan speed 50 nm/min. Far-UV CD
spectra were collated for standard BSA and BSA released in
PBS after 48 h, and the baseline acquired without the sample
was subtracted.32 The secondary structure of the samples was
estimated using the CDSSTR method33 protein reference set 3
from the DichroWeb server.34,35
Determination of BSA Activity.
A freshly prepared NPAES solution36 (15 :L of a 5 mM solution
in acetonitrile) was added to the released BSA sample (1.2 mL
in PBS, 50 :g/mL) and incubated for 1 h (HulaMixerTM Sample
Mixer). The absorbance of the sample mixture was measured
at 405 nm with standard BSA (50 :g/mL) used as a positive
control and PBS buffer alone as a negative control. The BSA
relative residual esterolytic activity was determined as the ra-
tio of absorbance between the released BSA to standard BSA.
The esterolytic activity for standard BSA was considered as
100%.
Cell Viability Studies.
A549 cells were cultured in RPMI-1640 medium containing
10% FCS/1% antibiotic/antimycotic solution (complete growth
medium—i). DCs were cultured in MEM alpha medium con-
taining ribonucleosides, deoxynucleosides, 4 mM L-glutamine,
1 mM sodium pyruvate 2 mM, supplemented with 20% FCS,
5 ng/mLmurine growthGM-CSF and 1% antibiotic/antimycotic
solution (complete growth medium—ii).
The toxicity profiles of NPs and NCMPs were assessed
over 24 h in A549 and of NPs only over 4 h in DCs using
MTT assay. Cells were cultured in 96-well plates with 100 :L
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(2.5 × 105 cells/mL) complete growth medium i and ii, respec-
tively, at 37◦C and 5% CO2. Then, complete growth medium
(100 :L) containing NPs (0–5 mg/mL) (n = 3) and 10% DMSO
as a positive control were added to the wells and incubated for a
further 4 h with DCs or with NPs and NCMPs (0–1.25 mg/mL)
(n = 3) for 24 h in A549 cells. This was followed by the addition
of 40 :L MTT solution (5 mg/mL in PBS, pH 7.4) to each well
and incubated for 2 h. The medium was then gently removed
(for DCs the 96-well plate was centrifuged at 1300g for 7 min
at 4◦C to pellet the suspended cells), and any formazan crystals
generated were solubilised with 100 :L of DMSO and the ab-
sorbance measured using a microplate reader (Epoch, BioTek
Instruments Ltd., UK) at 570 nm. The % cell viability was cal-
culated as the absorbance ratio betweenNPs orNCMPs-treated
and untreated control cells.
In Vitro NPs Uptake into DCs.
Dendritic cells uptake of FITC-BSA NPs was visualised using
confocal laser scanningmicroscopy (CLSM) (Carl Zeiss lsm 710,
UK) and image analysis was performed using Zeiss LSM soft-
ware The DCs (2 × 105 cells/400 :L) were plated into an eight-
well chambered borosilicate cover glass system, and incubated
at 37◦C and 5% CO2 for 48 h prior to treatment with NPs. The
FITC-BSA NPs (40 :g/40 :L) were placed in the wells and in-
cubated as above for 1 h. The suspensions from each well were
removed and washed using PBS. Cells were fixed for 15 min
with 300 :L of 4% paraformaldehyde in PBS followed by wash-
ing with PBS. The cell membranes were counterstained with
WGA TR and the nuclei were counterstained with DAPI added
to each well and incubated as above for 10 min, followed by
washing with PBS. The cells were examined using a CLSM
placed on a computer-controlled inverted microscope (Axiovert
200 M BP). Cells were imaged by excitation at a wavelength
of 595 nm (red channel for WGA TR), 358 nm (blue channel
for DAPI), 488 nm (green channel for FITC-BSA), with a Plan
Neofluar 63×/0.30 numerical aperture objective lens.
Statistical Analysis.
Minitab 16 Statistical Software R© (Minitab Inc.) was employed
for all statistical analysis and graph plotting. The data ob-
tained were analysed statistically by one-way ANOVA with the
Tukey’s comparison using Minitab 17.1 Statistical Software R©
(Minitab Inc.). Statistical significant difference was noted when
p < 0.05. Data are stated as the mean ± SD.
RESULTS
Optimisation of the BSA-Loaded NPs using Taguchi Design
The Taguchi L36 orthogonal array design required 36 runs to
be performed to ascertain the important factors influencing
the NP size and DL and to produce the optimum conditions
for each variable to achieve the smallest particle size NPs
(SPS NPs), and highest DL NPs (HDL NPs). Table 3 shows
the L36 orthogonal array and the measured NP size and DL.
Analysis of the results indicated particle sizes ranging from
216.2± 39.9 to 2168.9± 1553 nmandDL ranging from 0.8± 0.6
to 26.8 ± 5.8 :g/mg were obtained (Table 3).
Figures 1 and 2 show the mean S/N graph of the NP size and
DL of BSA, respectively, for each parameter level. The factor
with the largest range and corresponding rank (indicating the
Figure 1. Mean signal-to-noise (S/N) graph for particle size response.
Letters (A–H) indicate the experimental parameters and numeric value
indicates the parameter levels, ♦ indicates maximum S/N value. A,
IAP volume; B, OP volume; C, BSA concentration; D, polymer mass; E,
PVA concentration; F, IAP sonication time; G, EAP sonication time; H,
sonication amplitude.
Figure 2. Mean signal-to-noise (S/N) graph for BSA loading response.
Letters (A–H) indicate the experimental parameters and numeric value
indicates the parameter levels, ♦ indicates maximum S/N value. A,
IAP volume; B, OP volume; C, BSA concentration; D, polymer mass; E,
PVA concentration; F, IAP sonication time; G, EAP sonication time; H,
sonication amplitude.
relative importance compared with other factors) was consid-
ered as the significant factor influencing the size or DL.
The optimum conditions, based on the range, rank and
S/N graph (Fig. 1), for producing SPS NPs according to the
Taguchi’s ‘smaller-is-better’ criterion in Minitab R© 16 statisti-
cal software was A2B2C3D1E1F1G2H2. When this optimised
run was performed the measured particle size obtained was
203.0 ± 5.4 nm, which was lower than the minimum parti-
cle size of 216.2 ± 39.9 nm prepared using run 29. It is also
worth mentioning that the measured BSA loading of SPS NPs
was 35.9 ± 2.4 :g/mg. For the production of HDL NPs (Fig. 2)
using the Taguchi’s ‘larger-is-better’ criterion, the optimal con-
ditions were A2B1C3D1E1F3G3H2 which produced a DL of
43.67 ± 2.3 :g/mg. This was higher than the maximum DL of
26.8 ± 5.8 :g/mg obtained using run 24. The particle size of
HDL NPs was 287 ± 24.4 nm.
Optimisation of the Spray-Drying Process using Taguchi Design
Spray-drying was employed to encompass selected NP formu-
lations into NCMPs using L-leucine as a carrier and to enhance
powder dispersion. The Taguchi L27 orthogonal array design
required 27 runs to be performed to produce the optimum condi-
tion for each factor to achieve the highest yield % of dry powder.
Table 4 shows the structure of the Taguchi L27 orthogonal ar-
ray design and the measured dry powder yield % which ranged
from no yield to 49.8 ± 0.2%.
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Table 3. The Experimentally Measured Values of Particle Size (PS), Polydispersity Index (PI) and Drug Loading (DL) of NPs
Run A B C D E F G H PS (nm) PI DL (:g/mg)
1 1 1 1 1 1 1 1 1
574.4± 120.6 0.395± 0.15
3.6 ± 0.2
2 1 1 2 2 2 2 2 2
648.5± 10.5 0.209± 0.1
6.9 ± 0.4
3 1 1 3 3 3 3 3 3
1165.9± 337.9 0.181± 0.2
7.0 ± 0.1
4 1 1 1 1 1 1 2 2
498.7± 4.6 0.311± 0.01
2.4 ± 0.4
5 1 1 2 2 2 2 3 3
1032.9± 41.9 0.185± 0.3
5.7 ± 0.5
6 1 1 3 3 3 3 1 1
1534.7± 1484.00.172± 0.2
4.9 ± 3.4
7 1 1 1 1 2 3 1 2
577.8± 107.4 0.236± 0.1
4.1 ± 0.6
8 1 1 2 2 3 1 2 3
550.4± 93.9 0.146± 0.2
4.6 ± 0.9
9 1 1 3 3 1 2 3 1
1836.4± 864.0 0.273± 0.2
9.3 ± 0.2
10 1 2 1 1 3 2 1 3
357.5± 102.0 0.159± 0.03
0.8 ± 0.6
11 1 2 2 2 1 3 2 1 349 ± 68.9
0.124± 0.1
6.4 ± 0.9
12 1 2 3 3 2 1 3 2 325 ± 73.3
0.162± 0.03
4.3 ± 0.9
13 1 2 1 2 3 1 3 2
270.8± 81.0 0.133± 0.004
1.4 ± 0.5
14 1 2 2 3 1 2 1 3
416.4± 100.8 0.083± 0.1
3.9 ± 0.3
15 1 2 3 1 2 3 2 1
319.7± 41.9 0.142± 0.002
5.0 ± 4.0
16 1 2 1 2 3 2 1 1
493.1± 36.1 0.243± 0.06
1.9 ± 0.2
17 1 2 2 3 1 3 2 2
443.6± 47.0 0.135± 0.1
4.3 ± 0.2
18 1 2 3 1 2 1 3 3
230.7± 46.7 0.100± 0.01
15.7 ± 4.8
19 2 1 1 2 1 3 3 3
420.8± 75.9 0.081± 0.1
5.0 ± 0.1
20 2 1 2 3 2 1 1 1
1375.8± 392.2
0.005 ± 0 7.1 ± 0.1
21 2 1 3 1 3 2 2 2
467.3± 104.4
0.005 ± 0 19.2 ± 5.9
22 2 1 1 2 2 3 3 1
1204.7± 450.6 0.342± 0.1
5.6 ± 0.04
23 2 1 2 3 3 1 1 2
2168.9± 1553.00.003± 0.002
20.4 ± 0.7
24 2 1 3 1 1 2 2 3 267 ± 10.2
0.061± 0.07
26.8 ± 5.8
25 2 1 1 3 2 1 2 3
554.1± 88.7 0.111± 0.09
2.8 ± 0.1
26 2 1 2 1 3 2 3 1
468.2± 50.0 0.005± 0.0
15.8 ± 0.3
27 2 1 3 2 1 3 1 2
493.1± 104.0 0.046± 0.05
24.5 ± 3.1
28 2 2 1 3 2 2 2 1
535.1± 3.4 0.175± 0.1
2.7 ± 0.02
29 2 2 2 1 3 3 3 2
216.2± 39.9 0.104± 0.04
15.5 ± 0.9
30 2 2 3 2 1 1 1 3
343.4± 54.3 0.194± 0.03
17.7 ± 1.2
31 2 2 1 3 3 3 2 3
729.9± 54.6 0.269± 0.05
2.2 ± 0.4
32 2 2 2 1 1 1 3 1
246.5± 32.2 0.103± 0.02
18.8 ± 1.2
33 2 2 3 2 2 2 1 2
316.7± 59.8 0.212± 0.02
18.1 ± 0.1
34 2 2 1 3 1 2 3 2
430.1± 207.8 0.233± 0.1
3.1 ± 0.2
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Table 3. Continued
Run A B C D E F G H PS (nm) PI DL (:g/mg)
35 2 2 2 1 2 3 1 3
301.5± 19.6 0.095± 0.12
21.5 ± 1.9
36 2 2 3 2 3 1 2 1
463.5± 123.4 0.246± 0.03
19.2 ± 2.1
SPS 2 2 3 1 1 1 2 2
203.0± 5.4 0.201± 0.03
35.9 ± 2.4
HDL
2 1 3 1 1 3 3 2
287.0± 24.4 0.122± 0.05
43.7 ± 2.3
Data represent as mean ± SD, n = 3.
Note: A, IAP volume; B, organic phase volume; C, BSA concentration; D, polymer mass; E, PVA concentration; F, sonication time IAP; G, sonication time EAP; H, sonication
amplitude; DL, BSA loading; SPS, smallest particle size NPs; HDL, highest drug loading NPs.
Table 4. Spray-Drying Processing Variables for NCMPs Using Taguchi Design and Corresponding Yield%
Runs A B C D E Yield (%)
1 1 1 1 1 1 34.1 ± 2.2
2 1 1 1 1 2 30.5 ± 4.5
3 1 1 1 1 3 27.8 ± 0.3
4 1 2 2 2 1 26.5 ± 3.9
5 1 2 2 2 2 37.7 ± 0.7
6 1 2 2 2 3 29.4 ± 7.9
7 1 3 3 3 1 43.1 ± 2.4
8 1 3 3 3 2 41.9 ± 2.1
9 1 3 3 3 3 37.0 ± 1.0
10 2 1 2 3 1 0
11 2 1 2 3 2 0
12 2 1 2 3 3 0
13 2 2 3 1 1 49.8 ± 0.2
14 2 2 3 1 2 41.2 ± 0.1
15 2 2 3 1 3 40.8 ± 3.5
16 2 3 1 2 1 38.2 ± 1.2
17 2 3 1 2 2 33.3 ± 0.8
18 2 3 1 2 3 26.6 ± 1.2
19 3 1 3 2 1 48.6 ± 2.5
20 3 1 3 2 2 35.8 ± 2.7
21 3 1 3 2 3 35.7 ± 3.1
22 3 2 1 3 1 0
23 3 2 1 3 2 0
24 3 2 1 3 3 0
25 3 3 2 1 1 38.0 ± 1.1
26 3 3 2 1 2 21.9 ± 0.9
27 3 3 2 1 3 24.0 ± 1.5
H 1 3 3 2 1 50.9 ± 2.3
Data represent mean ± SD, n = 3.
Note: A, air flow; B, inlet temperature; C, aspirator%; D, pump rate; E, feed concentration. Numeric values 1–27 indicate experimental run number, H indicate optimum
spray-drying condition that produce highest yield%.
Figure 3 presents the mean S/N graph of the yield % for
each factor level. The factor with the largest range and cor-
responding rank (indicating the relative importance compared
with other factors) was regarded as the significant factor influ-
encing the yield %. Optimum specifications were determined
by high S/N ratios. Based on the range, rank and S/N response
graph, production of highest dry powder yield % according to
the Taguchi’s ‘larger-is-better’ criterion in Minitab 16 statis-
tical software suggested combinations A1B3C3D2E1 (run H—
Table 4). When run H was performed the dry powder yield %
was 50.9 ± 2.3%.
Figure 4 represents the SEM photomicrographs of NCMPs
and run H regarding the shape and surface morphology, which
was irregular and porous microparticle carriers. The selected
HDL NPs and SPS NPs were spray-dried using run H param-
eters (because it produced the highest yield% of powder ∼50%)
to produce NCMPs. The formulations were given the following
Figure 3. Mean signal-to-noise (S/N) graph for yield % response. Let-
ters (A–E) indicate the experimental parameters and numeric value
indicates the parameter levels, ♦ indicates maximum S/N value. A,
airflow; B, inlet temperature; C, aspirator %; D, feed rate %; E, feed
concentration.
DOI 10.1002/jps.24681 ALFAGIH ET AL., JOURNAL OF PHARMACEUTICAL SCIENCES
Author Proof
8 RESEARCH ARTICLE – Pharmaceutical Nanotechnology
Figure 4. SEM images of NCMPs prepared by different spray-drying
conditions (numeric values 1–27 indicates run experimental number,
H: NCMPs spray-dried with run H (HDL HNCMPs), L: L-leucine alone
spray-dried with run H. The scale bar represents 1 :m.
codes: HDL H NCMPs, and SPS H NCMPs. Formulations SPS
H NCMPs and HDL H NCMPs were carried out for further
investigations. The NCMPs had a residual moisture content of
0.2 ± 0.03% (w/w).
Primary Aerodynamic Diameter and In Vitro Aerosolisation
Studies for NCMPs
There was no significant difference between NCMPs formula-
tions regarding geometric particle size (HDL: 3.89 ± 0.37 and
SPS: 4.69± 0.77 :m) (p > 0.05). However, significant difference
(p < 0.05) was observed between the NCMPs formulations with
respect to tapped density and carr’s index. The theoretical aero-
dynamic diameter (dae) was calculated from both these param-
eters and ranged from 1.45± 0.14 and 1.71± 0.32 :m (Table 5)
indicating the suitability for pulmonary delivery, but no signif-
Figure 5. Cumulative in vitro release of BSA from NCMPs in PBS
buffer at 37◦C. (Data represent mean ± SD, n = 3.)
icant difference (p ? 0.05). BSA deposition data obtained from
NCMPs (Table 6) indicated there was no significant difference
in FPD and MMAD (p ? 0.05), but HDL H NCMPs achieved a
significantly higher FPF (p < 0.05) between the formulations
examined.
In Vitro Release Studies
In vitro release studies comparing SPS H NCMPs and HDL
H NCMPs formulations were performed (Fig. 5) and showed
a biphasic release profile. An initial burst release was ob-
served up to 4 h with BSA release from HDL H NCMPs
(18.46 ± 0.92%) significantly greater than SPS H NCMPs
(9.09 ± 3.4%) (p < 0.05) followed by a continuous release over
48 h. A significant difference (p < 0.05) was noted in the release
profile (24–48 h) between HDL H NCMPs and SPS H NCMPs,
with HDL H NCMPs achieving 38.77 ± 3% release after 48 h
compared with 20.84 ± 4.2% for SPS H NCMPs .
In this study, BSA was released from SPS H NCMPs
and HDL H NCMPs following the Higuchi diffusion model
(r2 = 0.981 and 0.955, respectively) with a release rate constant
(k1, h
−
1
/2) of 2.7021 and 5.3653, respectively (Table 7). Hence,
the release of BSA from NCMPs seems to be a diffusion-limited
process. Accordingly HDL H NCMPs was selected for further
investigation in this study.
Investigation of BSA Structure and Activity
The primary structure of BSA released from NPs and NCMPs
was analysed by SDS-PAGE (Fig. 6). The BSA standard and
molecular weight marker shown in lanes 1 and 5, respectively,
revealed a clear band at about 66 kDa. The BSA released from
HDL NPs (lane 2) and from HDL H NCMPs (lanes 3 and 4),
showed similar clear banding patterns to the BSA standard
(Fig. 6). The single lines in the gels provided evidence that the
BSA released did not undergo significant covalent aggregation
or fragmentation during the formulation methods used. The
residual esterolytic activity of the BSA sample was evaluated
to be 74.98 ± 5.8% relative to standard BSA.
The secondary structure of BSAwas analysed using CD spec-
troscopy (Fig. 7). The structure of standard BSA and BSA re-
leased, indicated minima at 221–222 and 209–210 nm and a
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Table 5. The Geometric Particle Size, Tapped Density and Theoretical Aerodynamic Diameter of Spray-Dried NCMPs
Formulation Particle size (:m) Tapped density (g/cm3) Carr’s Index d ae (:m)
% Flowability
SPS H NCMPs 4.69 ± 0.77 0.132 ± 0.007* 36.21 ± 1.5* Very poor 1.71 ± 0.32
HDL H NCMPs 3.89 ± 0.37 0.145 ± 0.002 31.25 ± 1.7 Poor 1.46 ± 0.14
Data represent mean ± SD, n = 3.
*p < 0.05, ANOVA/Tukey’s comparison.
Table 6. The Fine Particle Dose (FPD), Percentage Fine Particle Fraction (FPF) and Mass median Aerodynamic Diameter (MMAD) of NCMPs
Formulation FPD (:g) FPF (%) MMAD (:m)
SPS H NCMPs 38.04 ± 2.80 64.32 ± 1.6* 1.49 ± 0.13
HDL H NCMPs 45.00 ± 7.40 78.57 ± 0.1 1.71 ± 0.10
Data represent mean ± SD, n = 3.
*p < 0.05, ANOVA/Tukey’s comparison.
Table 7. Release Parameters of BSA from NCMPs
Formulation Zero Order First Order Higuchi
r 2 k o (h
−1) r 2 k 1 (h
−1) r 2 k 1 (h
−
1
/2)
HDL H NCMPs 0.842 0.72 0.886 −0.004 0.955 5.3653
SPS H NCMPs 0.881 0.366 0.899 −0.0018 0.981 2.7021
Figure 6. SDS-PAGE behaviour of BSA released for the assessment
of BSA stability. Lanes represent, BSA standard (1), BSA released from
HDL NPs (2), BSA released from HDL H NCMPs (3, 4), and molecular
weight (MW) standard markers, BSA (MW 66,000), (5). Difference in
band intensity was due to different loading.
maximum at 195 nm for both samples, which is typical for "-
helical structure. In support of these data, structural analysis
showed that BSA was predominantly helical displaying 51.5%
helicity (Table 8), which is in good agreement with Zhang et
al.37 Structural analysis of BSA released displayed double min-
ima at 210 and 222 nm and a further spectra analysis showed
Figure 7. The CD spectra of BSA released from HDL NPs (grey) and
BSA standard (black).
a reduced level of "-helical conformation (circa 48.5% helical)
(Table 8). Furthermore, a comparison of BSA released with
standard BSA showed that the "-helical content decreased by
3%.
Cell Viability Studies and NPs Cellular Uptake by DCs
The unloaded NPs and NCMPs appeared to be well tolerated
by the A549 cell line, with a cell viability of 84.63 ± 5% for NPs
and 75.7 ± 4% for NCMPs (Fig. 8) at 1.25 mg/mL concentration
after 24 h exposure. In addition, the unloaded NPs displayed a
cell viability of 86.38± 5.5% at 5 mg/mL concentration after 4 h
exposure in DCs, indicating good cell viability with increasing
NP concentration (Fig. 9).
Figure 10 shows the intracellular localisation of FITC-BSA-
loaded NPs inside DCs after 4 h incubation. The cell wall of the
DCs was stained with WGA TR, the nucleus was stained with
DAPI and the NPs loaded with FITC-BSA were observed under
red, blue and green channels, respectively. The green fluores-
cence was observed inside the DCs confirming the presence of
NPs.
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Table 8. The Percentage of Secondary Structure Conformation for BSA Released from the Selected Formulation and BSA Standard
Sample Helix Strands Turns Unordered
BSA standard 51.5 ± 0.007 21.50 ± 0.007 9.0 ± 0 17.50 ± 0.007
BSA released 48.50 ± 0.007 25.0 ± 0 6.50 ± 0.007 19.5 ± 0.007
Data represent mean ± SD, n = 3.
Figure 8. A549 cell viability measured by MTT assay after 24 h ex-
posure to NPs and NCMPs. (Data represent mean ± SD, n = 3.)
Figure 9. DCs viability measured by MTT assay after 4 h exposure
to NPs. (Data represent mean ± SD, n = 3).
DISCUSSION
Preparation and Characterisation of NPs
The loading capacity of NPs is a critical aspect for delivery as
high loading results in greater bioavailability of drug per parti-
cle absorbed.38 A successful drug delivery system should have
a high loading capability which will decrease the amount of
drug and excipients used for manufacturing the delivery sys-
tem. Analysis of the results from the Taguchi design indicated
that the DL of NPs was influenced by different parameters in
the following order: BSA concentration > IAP volume > poly-
mer mass > PVA concentration > OP volume > EAP sonication
time and IAP sonication time > sonication amplitude; whereas
the influence on the particle size of NPs had the following or-
der: polymer mass > OP volume > sonication amplitude > sur-
factant concentration > EAP sonication time IAP sonication
time > IAP volume > BSA concentration.
Bovine serum albumin concentration (rank 1; Fig. 2) had
the greatest influence on the DL which increased profoundly as
the BSA concentration increased from 0.2% to 1%. This was ex-
pected from predictions based on Eq. 1 in which DL is positively
proportional to the amount of BSA38 and can be seen comparing
run 7 (4.1± 0.6 :g/mg) and run 18 (15.7± 4.8 :g/mg). However,
increasing the BSA concentration to large levels (1%) is not nec-
essarily beneficial; this trend has been explained by the mass
of polymer used being insufficient to completely encapsulate
the BSA.38 Furthermore, higher concentrations of BSA provide
a higher concentration in IAP droplets and thus increase the
concentration gradient between the IAP droplets and the EAP,
resulting in an increased amount of BSA transported into the
EAP.39,40 IAP volume (rank 2; Fig. 2) plays an important role
on DL, such that, the larger volume of the IAP the higher the
BSA loading, as seen in run 13 (1.4 ± 0.5 :g/mg) and run 19
(5.0 ± 0.1 :g/mg) (Table 3). This effect has been reported38,41
and is thought to be due to a decrease in the concentration
gradient between IAP and EAP.
The third factor affecting DL was the polymer mass (rank
3; Fig. 2). DL decreased substantially with increasing poly-
mer mass from 50 to 200 mg, as predicted based on Eq. 1,
in which DL is inversely proportional to the polymer mass.42
This trend can be seen in run 22 (5.6 ± 0.04 :g/mg) and run 25
(2.8± 0.1 :g/mg). In addition, the results showed that reducing
the OP volume (rank 5; Fig. 2) increased DL. This was associ-
ated with the high viscosity of the OP resulting in enhanced
primary emulsion stabilisation and minimising the diffusion
rate of BSA through the OP.41
The fourth factor affecting DL was PVA concentration, with
1% PVA resulting in higher BSA loading as seen comparing run
19 (5.0 ± 0.1 :g/mg) and run 22 (5.6 ± 0.04 :g/mg) (Fig. 2).
A possible explanation was that at this concentration PVA
was adequate to completely cover the partition interface (or-
ganic/aqueous) and subsequently resulting in reduced leaching
of BSA. Consequently, any further increase in PVA concentra-
tion (5% and 10%) resulted in decreased DL because of the
enhanced partitioning of BSA into the aqueous phase during
emulsification. This was attributed to the solubilisation and
emulsification effect of PVA.43
Sonication time of the EAP and IAP exerted similar effects
on DL where increasing the sonication time of IAP and EAP
resulted in higher DL.44 The factor that had the least effect
was sonication amplitude. Increasing the sonication amplitude
(30% to 45% to 65%) had almost no beneficial effect on the BSA
loading. This effect has been reported previously and has been
associated with BSA precipitation within the sonication probe
due to high pressure and increased fluid cavitations during
sonication.45,46
Analysis of results following the Taguchi design indicated
that the particle size of NPs was influenced by different param-
eters in the following order: polymer mass>OP volume> soni-
cation amplitude > surfactant concentration > EAP sonication
time and IAP sonication time > IAP volume > BSA concen-
tration. It can be seen that the polymer mass followed by the
OP volume (rank 1 and 2; Fig. 1) had the greatest effect on
NPs size. An increase polymer mass resulted in an enhanced
NP size, with run 3, 6, 9, 20 and 23 achieving the largest NPs
size (Table 3). This was demonstrated by the observation that
PGA-co-PDL mass was the primary parameter accountable for
the variation in NPs size. A similar observation has also been
noted by Bilati et al.38 investigating PLGA NPs encapsulated
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Figure 10. Confocal microscopic image of FITC-BSA NPs uptake by DCs. (a) DCs incubated without NPs at 20×, (b) DCs incubated with
FITC-BSA NPs at 20×, (c) DCs incubated with FITC-BSA NPs at 63×, red channel for WGA TR, blue channel for DAPI and green channel for
FITC-BSA.
with protein prepared using a double emulsion solvent evap-
oration method or with microparticles. The effect of polymer
mass on the particle size has also been attributed to the in-
creased viscosity and subsequent less proficient stirring of the
OP leading to an greater NPs coalescence.47
Poly(vinyl alcohol) concentration was directly proportional
to size with a trend of 1 < 5 < 10% PVA (rank 4; Fig. 1).
This was associated with an increase in viscosity with increase
in PVA concentration in the IAP corresponding to a reduced
shear stress, decreased diffusion rate and consequently in-
crease in NP size. This can be seen comparing run 4 (1% PVA,
498.7± 4.6 nm) and run 7 (5%PVA, 577.8± 107.4 nm) (Table 3).
Furthermore, additions of more PVA lead to an enlargement in
NPs size because of the buildup of surplus molecules at the
surface leading to bridging between the primary particles.43
BSA concentration and IAP volume had minimum effect on the
particle size of NPs which has also previously been reported in
literature.38
The rate of size reduction decreased considerably when son-
ication was carried out beyond the duration of 5 s for IAP (rank
6) or 15 s for EAP (rank 5) or beyond the amplitude (rank 3)
of 45% (Fig. 1). Increasing amplitude lead to more fluid cavi-
tation, this inhibits the efficiency of energy transmission and
decreased ultrasonic effect.48 This can be seen in run 10 and
29 (Table 3) which differ in amplitude (65% and 45%, respec-
tively), sonication time for IAP (10 and 15 s, respectively) and
EAP (10 and 30 s, respectively)
Precise adjustment of the numerous formulation and pro-
cessing factors is important to attain the desired NPs size
and BSA loading. In this study, a particle size of ≤500 nm
was desired to facilitate uptake of NPs by DCs.6,7,49 A high
S/N ratio suggested optimum conditions such that, the larger
the S/N ratio, the less variance of particle size and BSA load-
ing from the desired value. When the suggested optimized run
was carried out, the measured particle size (SPS NPs) obtained
203 ± 5.4 nm was considered suitable for DCs uptake.50–52
NCMP Characterisation
Spray-drying was utilised to encompass the selected NPs into
NCMPs with L-leucine as a carrier and to enhance powder
dispersion. Majority of the spray-drying process parameters
achieved low yields because of the condensation inside the dry-
ing chamber and collecting vessel resulting in the dry particles
sticking to the walls.53 Utilising the Taguchi design revealed
that the feed rate, aspirator capacity, air flow and inlet tem-
perature had the greatest effects on the yield% of dry powder,
whereas the change in the concentration of total solid in the
spray-dried suspension had no effect in the yield% of dry pow-
der.
The most important factor was feed rate (rank 1; Fig. 3) with
a negative effect on powder yield. At high feed rates 15%, it
is difficult for the atomized air to penetrate the liquid stream.
Consequently, insufficient atomisation and drying will result
with large NCMPs deposition and sticking to the walls in the
drying and cyclone chambers.53
The second important factor was aspirator flow (rank 2;
Fig. 3) with a positive effect on powder yield% (rank 2). A high
aspirator flow rate created greater centrifugal force leading to
an increase in the collection efficiency.54 Airflow had a negative
effect on powder yield% (rank 3; Fig. 3). Higher spray flow pro-
duced smaller droplets which were collected less efficiently by
the centrifugal force in the cyclone.54
The inlet temperature (rank 4; Fig. 3) of drying air ranged
from 50◦C to 100◦C, typically resulting in an outlet tempera-
ture of approximately 22◦C to 46◦C. It was noticed that as the
inlet temperature increased from 50◦C to 100◦C there was an
increase in powder yield%. It has been reported that a high
inlet temperature can reduce the drying time and inhibit par-
ticle aggregation.55 Furthermore, a higher inlet temperature
promotes a decrease in residual moisture by enhancing water
evaporation resulting in less particles sticking in the drying
chamber.56
The results obtained from spray-drying regarding runs 10,
11, 12, 22, 23 and 24 produced no yield. They all shared the
predominant factor (Feed Rate, rank 1; Fig. 3) affecting yield
although they differed in other factors (aspirator capacity, air
flow and inlet temperature) (Table 4). The feed rate was 15%,
and at this high rate the atomising air may not be able to
break the flow of the suspension. Furthermore, the high feed
rate was accompanied by low level of aspirator capacity (50%
and 75%), high level airflow (535 and 670 L/h) and low level
of inlet temperature (50◦C and 75◦C), which all had negative
effect on yield as explained above.When these parameters were
adjusted to their positive level in run 7, 8 and 9 (Table 4) the
yield increased up to 43%.
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Photomicrographs showed irregular and porous NCMPs.
This has been associated with vapour pressure that builds up
during the removal of water throughout spray-drying and is
prevalent with L-leucine and other hydrophobic amino acids,
resulting in improved aerosolisation.57 Furthermore, photomi-
crographs of NCMPs were similar irrespective of different pro-
cessing conditions. High residual moisture content can pro-
mote particle aggregation leading to a variation in particle size
distribution.58 The lowmoisture content reported from the TGA
thermogram presents a good drying efficiency therefore the dry
powder formulations are likely to show good storage stability.
In Vitro Release and Aerosolisation Studies
Aerosolisation deposition data of NCMPs formulations indi-
cated a similarity in FPD. The significantly higher FPF% of
HDL H NCMPs compared with SPS H NCMPs was attributed
to powder aggregation which was demonstrated by the large
Carr’s index, ≥32, implying the flow of SPS H NCMPs was very
poor. In addition, SPS H NCMPs had a significantly smaller
MMAD indicating possibility of aggregation and
In vitro release studies comparing SPS H NCMPs and HDL
H NCMPs formulations were performed, with our results in-
dicating a diffusion-limited process according to the Higuchi
diffusion model. The observed change in release profile at 24 h
following the initial burst release could be attributed to the dis-
tribution of BSA within NPs and/or alteration in degradation
rate due to changed surface porosity.24
Stability of BSA and Cell Viability Studies
The primary structure of BSA released from HDL NPs and
HDL H NCMPs showed similar clear banding patterns to the
BSA standard provided evidence that the released BSA did not
suffer significant covalent aggregation or fragmentation during
the preparation methods used.
The secondary structure of BSA released was analysed using
CD spectroscopy, a valuable technique in analysing the protein
structure.31 The spectra confirmed the presence of "-helix in
the BSA released samples although this was decreased in com-
parison with standard BSA.
Bovine serum albumin has an enzyme-like activity and is
able to hydrolyse substrates such as p-nitophenyl esters.36
When compared with standard BSA, the released BSA sample
maintained approximately 74% of relative residual esterolytic
activity, which was higher than 60% obtained by Abbate et al.36
The reduction seen in this study was possibly due to the en-
capsulation process which resulted in a reduction in helicity
as evaluated by CD (Fig. 7 and Table 8), and hence BSA ac-
tivity. However, a 74% retention in activity achieved using this
delivery system is still promising for further investigation of
macromolecule delivery including proteins for vaccine.
The influence of NPs and NCMPs on cell viability studies
were performed on the A549 and JAWS II DC lines. The NPs
and NCMPs appear to be well tolerated by both cell lines. Al-
though a decrease in cell viability was observed with increasing
NPs and NCMPs concentration in both cell lines (A549: >75%
at 1.25 mg/mL and DC: >85% at 5 mg/mL concentration), a
high DL was obtained, which indicates lower doses could be
delivered, hence negating the potential toxicity at high doses.
Moreover, the dose delivered would be distributed throughout
the lung and not localise within specific sites at these high
concentrations.59
The uptake of NPs by JAWS II DC type was confirmed by
CLSM. Thus NPs are efficiently ingested by DCs and could be
applied for the delivery of antigens to DCs.
CONCLUSIONS Q5
The PGA-co-PDL NPs with appropriate size (203 ± 5.4 nm) to
target DCs and BSA loading (43.67 ± 2.3 :g/mg) were success-
fully prepared using the Taguchi L36 orthogonal array design
of experiment method. Selected NPs formulations were incor-
porated into NCMPs using L-leucine as a carrier. The highest
yield% of dry powder (50%) was obtained using the Taguchi L27
orthogonal array design of experiment. The NCMPs had irreg-
ular and porous surface. The in vitro release studies indicated
BSA maintains its primary and secondary structure. Further-
more, aerosolisation deposition data (FPF 78.57 ± 0.1% and
MMAD 1.71 ± 0.1 :m) indicate deep lung deposition. In addi-
tion, the NPs and NCMPs had a relatively high cell viability
(A549:>75% at 1.25 mg/mL and DC:>85% at 5 mg/mL concen-
tration) at high concentrations. This study suggests that PGA-
co-PDL NCMPs could be further investigated for pulmonary
delivery of macromolecules, including the possibility for vac-
cine delivery via the pulmonary route.
ACKNOWLEDGMENT
This research project was supported by a grant from the ‘Re-
search Centre of the Centre for Female Scientific and Medical
Colleges’, Deanship of Scientific Research, King Saud Univer-
sity.
REFERENCES
1. Reichert JM. 2003. Trends in development and approval times for
new therapeutics in the United States. Nat Rev Drug Discov 2(9):695–
702.
2. Kunda NK, Somavarapu S, Gordon SB, Hutcheon GA, Saleem IY.
2013. Nanocarriers targeting dendritic cells for pulmonary vaccine de-
livery. Pharm Res 30(2):325–341.
3. Sou T, Meeusen EN, de Veer M, Morton DA, Kaminskas LM, McIn-
tosh MP. 2011. New developments in dry powder pulmonary vaccine
delivery. Trends Biotechnol 29(4):191–198.
4. Pulliam B, Sung JC, Edwards DA. 2007. Design of nanoparticle-
based dry powder pulmonary vaccines. Expert Opin Drug Deliv
4(6):651–663.
5. Rytting E, Nguyen J, Wang X, Kissel T. 2008. Biodegradable poly-
meric nanocarriers for pulmonary drug delivery. Expert Opin Drug
Deliv 5(6):629–639.
6. Foged C, Brodin B, Frokjaer S, Sundblad A. 2005. Particle size and
surface charge affect particle uptake by human dendritic cells in an in
vitro model. Int J Pharm 298(2):315–322.
7. Kunda NK, Alfagih IM, Dennison SR, Tawfeek HM, Somavarapu S,
Hutcheon GA, Saleem IY. 2015. Bovine serum albumin adsorbed PGA-
co-PDL nanocarriers for vaccine delivery via dry powder inhalation.
Pharm Res 32(4):1341–1353.
8. Kallinteri P, Higgins S, Hutcheon GA, St Pourcain CB, Garnett
MC. 2005. Novel functionalized biodegradable polymers for nanoparti-
cle drug delivery systems. Biomacromolecules 6(4):1885–1894.
9. Thompson CJ, Hansford D, Higgins S, Rostron C, Hutcheon GA,
Munday DL. 2007. Evaluation of ibuprofen-loaded microspheres pre-
pared from novel copolyesters. Int J Pharm 329(1–2):53–61.
10. Tawfeek H, Khidr S, Samy E, Ahmed S, Murphy M, Mohammed A,
Shabir A, Hutcheon G, Saleem I. 2011. Poly(glycerol adipate-co-omega-
ALFAGIH ET AL., JOURNAL OF PHARMACEUTICAL SCIENCES DOI 10.1002/jps.24681
Author Proof
RESEARCH ARTICLE – Pharmaceutical Nanotechnology 13
pentadecalactone) spray-dried microparticles as sustained release car-
riers for pulmonary delivery. Pharm Res 28(9):2086–2097.
11. Tawfeek HM, Evans AR, Iftikhar A, Mohammed AR, Shabir A,
Somavarapu S, Hutcheon GA, Saleem IY. 2013. Dry powder inhalation
of macromolecules using novel PEG-co-polyestermicroparticle carriers.
Int J Pharm 441(1–2):611–619.
12. Lu D, Hickey AJ. 2007. Pulmonary vaccine delivery. Expert Rev
Vaccines 6(2):213–226.
13. Stocke NA, Meenach SA, Arnold SM, Mansour HM, Hilt JZ. 2015.
Formulation and characterization of inhalable magnetic nanocompos-
ite microparticles (MnMs) for targeted pulmonary delivery via spray
drying. Int J Pharm 479(2):320–328.
14. Ungaro F, d’Angelo I, Miro A, La Rotonda MI, Quaglia F. 2012.
Engineered PLGA nano- and micro-carriers for pulmonary delivery:
Challenges and promises. J Pharm Pharmacol 64(9):1217–1235.
15. Sinsuebpol C, Chatchawalsaisin J, Kulvanich P. 2013. Preparation
and in vivo absorption evaluation of spray dried powders containing
salmon calcitonin loaded chitosan nanoparticles for pulmonary deliv-
ery. Drug Des Devel Ther 7:861–873.
16. McBride AA, Price DN, Lamoureux LR, Elmaoued AA, Vargas JM,
Adolphi NL, Muttil P. 2013. Preparation and characterization of novel
magnetic nano-in-microparticles for site-specific pulmonary drug deliv-
ery. Mol Pharm 10(10):3574–3581.
17. Amaro MI, Tajber L, Corrigan OI, Healy AM. 2011. Optimisation
of spray drying process conditions for sugar nanoporous microparticles
(NPMPs) intended for inhalation. Int J Pharm 421(1):99–109.
18. Amaro MI, Tewes F, Gobbo O, Tajber L, Corrigan OI, Ehrhardt
C, Healy AM. 2015. Formulation, stability and pharmacokinetics of
sugar-based salmon calcitonin-loaded nanoporous/nanoparticulate mi-
croparticles (NPMPs) for inhalation. Int J Pharm 483(1–2):6–18.
19. Belotti S, Rossi A, Colombo P, Bettini R, Rekkas D, Politis S,
Colombo G, Balducci AG, Buttini F. 2014. Spray dried amikacin powder
for inhalation in cystic fibrosis patients: A quality by design approach
for product construction. Int J Pharm 471(1–2):507–515.
20. Razavi Rohani SS, Abnous K, Tafaghodi M. 2014. Preparation and
characterization of spray-dried powders intended for pulmonary deliv-
ery of insulin with regard to the selection of excipients. Int J Pharm
465(1–2):464–478.
21. Al-fagih I, Alanazi F, HutcheonG, Saleem I. 2011. Recent Advances
Using Supercritical Fluid Techniques for Pulmonary Administration of
Macromolecules via Dry Powder Formulations. Drug Delivery Letters
1:128–134.
22. Li X, Vogt FG, Hayes D , Jr., Mansour HM. 2014. Design, charac-
terization, and aerosol dispersion performance modeling of advanced
co-spray dried antibiotics with mannitol as respirable microparti-
cles/nanoparticles for targeted pulmonary delivery as dry powder in-
halers. J Pharm Sci 103(9):2937–2949.
23. Osman R, Al Jamal KT, Kan PL, Awad G, Mortada N, El-Shamy
AE, Alpar O. 2013. Inhalable DNase I microparticles engineered with
biologically active excipients. Pulm Pharmacol Ther 26(6):700–709.
24. Jensen DM, CunD,MaltesenMJ, Frokjaer S, NielsenHM, Foged C.
2010. Spray drying of siRNA-containing PLGA nanoparticles intended
for inhalation. J Control Release 142(1):138–145.
25. Yang SC, Zhu JB. 2002. Preparation and characterization of camp-
tothecin solid lipid nanoparticles. Drug Dev Ind Pharm 28(3):265–274.
26. Lee SH, Heng D, Ng WK, Chan HK, Tan RB. 2011. Nano spray
drying: A novel method for preparing protein nanoparticles for protein
therapy. Int J Pharm 403(1–2):192–200.
27. Thompson CJ, Hansford D, Higgins S, Hutcheon GA, Rostron C,
Munday DL. 2006. Enzymatic synthesis and evaluation of new novel
T-pentadecalactone polymers for the production of biodegradable mi-
crospheres. J Microencapsul 23(2):213–226.
28. Taguchi G, Yokoyama Y. 1993. Taguchi methods: Design of experi-
ments. ASI Press.Q6
29.WongW, Crapper J, Chan HK, Traini D, Young PM. 2010. Pharma-
copeial methodologies for determining aerodynamic mass distributions
of ultra-high dose inhaler medicines. J Pharm Biomed Anal 51(4):853–
857.
30. Myrdal PB, Yalkowsky SH. 2007. Solubilization of drugs in aqueous
media. In Encyclopedia of pharmaceutical technology; Swarbrick J , Ed.
3rd ed. New York: Informa Health Care. p 3311.
31. Greenfield NJ. 2006. Using circular dichroism spectra to estimate
protein secondary structure. Nat Protoc 1(6):2876–2890.
32. Henzler Wildman KA, Lee DK, Ramamoorthy A. 2003. Mechanism
of lipid bilayer disruption by the human antimicrobial peptide, LL-37.
Biochemistry 42(21):6545–6558.
33.Whitmore L, Woollett B, Miles AJ, Janes RW, Wallace BA. 2010.
The protein circular dichroism data bank, a Web-based site for access
to circular dichroism spectroscopic data. Structure 18(10):1267–1269.
34.Whitmore L, Wallace BA. 2004. DICHROWEB, an online server for
protein secondary structure analyses from circular dichroism spectro-
scopic data. Nucleic Acids Res 32(Web Server issue):W668–673.
35.Whitmore L, Wallace BA. 2008. Protein secondary structure anal-
yses from circular dichroism spectroscopy: Methods and reference
databases. Biopolymers 89(5):392–400.
36. Abbate V, Kong X, Bansal SS. 2012. Photocrosslinked bovine serum
albumin hydrogels with partial retention of esterase activity. Enzyme
Microb Technol 50(2):130–136.
37. Zhang J, Ma X, Guo Y, Yang L, Shen Q, Wang H, Ma Z. 2010.
Size-controllable preparation of bovine serum albumin-conjugated PbS
nanoparticles. Mater Chem Phys 119(1–2):112–117.
38. Bilati U, Allemann E, Doelker E. 2005. Poly(D,L-lactide-co-
glycolide) protein-loaded nanoparticles prepared by the double emul-
sion method–processing and formulation issues for enhanced entrap-
ment efficiency. J Microencapsul 22(2):205–214.
39. Bittner B, Kissel T. 1999. Ultrasonic atomization for spray drying: A
versatile technique for the preparation of protein loaded biodegradable
microspheres. J Microencapsul 16(3):325–341.
40. Yang YY, Chung TS, Ng NP. 2001. Morphology, drug distribu-
tion, and in vitro release profiles of biodegradable polymeric micro-
spheres containing protein fabricated by double-emulsion solvent ex-
traction/evaporation method. Biomaterials 22(3):231–241.
41. Cun D, Jensen DK, Maltesen MJ, Bunker M, Whiteside P, Scurr D,
Foged C, Nielsen HM. 2011. High loading efficiency and sustained re-
lease of siRNA encapsulated in PLGA nanoparticles: Quality by design
optimization and characterization. Eur J Pharm Biopharm 77(1):26–
35.
42. Brunner CT, Baran ET, Pinho ED, Reis RL, Neves NM. 2011. Per-
formance of biodegradable microcapsules of poly(butylene succinate),
poly(butylene succinate-co-adipate) and poly(butylene terephthalate-
co-adipate) as drug encapsulation systems. Colloids Surf B Biointer-
faces 84(2):498–507.
43. Sanad RA, Abdel Malak NS, El-Bayoomy TS, Badawi AA. 2010.
Preparation and characterization of oxybenzone-loaded solid lipid
nanoparticles (SLNs) with enhanced safety and sunscreening efficacy:
SPF and UVA-PF. Drug Discov Ther 4(6):472–483.
44.Walter E, Moelling K, Pavlovic J, Merkle HP. 1999. Microencapsu-
lation of DNA using poly(DL-lactide-co-glycolide): Stability issues and
release characteristics. J Control Release 61(3):361–374.
45.Wischke C, Borchert HH. 2006. Influence of the primary emulsifi-
cation procedure on the characteristics of small protein-loaded PLGA
microparticles for antigen delivery. J Microencapsul 23(4):435–448.
46. Zhang JX, Chen D, Wang SJ, Zhu KJ. 2005. Optimizing dou-
ble emulsion process to decrease the burst release of protein from
biodegradable polymer microspheres. J Microencapsul 22(4):413–422.
47. Li X, Deng X, Yuan M, Xiong C, Huang Z, Zhang Y, Jia W. 1999.
Investigation on process parameters involved in preparation of poly-
DL-lactide-poly(ethylene glycol) microspheres containing Leptospira
Interrogans antigens. Int J Pharm 178(2):245–255.
48. Tang ES, Huang M, Lim LY. 2003. Ultrasonication of chitosan and
chitosan nanoparticles. Int J Pharm 265(1–2):103–114.
49. Slutter B, Bal S, Keijzer C, Mallants R, Hagenaars N, Que I, Kaijzel
E, van Eden W, Augustijns P, Lowik C, Bouwstra J, Broere F, Jiskoot
W. 2010. Nasal vaccination with N-trimethyl chitosan and PLGA
based nanoparticles: Nanoparticle characteristics determine quality
and strength of the antibody response in mice against the encapsu-
DOI 10.1002/jps.24681 ALFAGIH ET AL., JOURNAL OF PHARMACEUTICAL SCIENCES
Author Proof
14 RESEARCH ARTICLE – Pharmaceutical Nanotechnology
lated antigen. Vaccine 28(38):6282–6291.
50. Gutierro I, Hernandez RM, Igartua M, Gascon AR, Pedraz JL.
2002. Size dependent immune response after subcutaneous, oral and
intranasal administration of BSA loaded nanospheres. Vaccine 21(1–
2):67–77.
51. Shakweh M, Ponchel G, Fattal E. 2004. Particle uptake by Peyer’s
patches: A pathway for drug and vaccine delivery. Expert Opin Drug
Deliv 1(1):141–163.
52. des Rieux A, Fievez V, Garinot M, Schneider YJ, Preat V. 2006.
Nanoparticles as potential oral delivery systems of proteins and vac-
cines: A mechanistic approach. J Control Release 116(1):1–27.
53. Motlekar N. 2009. Optimization of experimental parameters for the
production of LMWH-loaded polymeric microspheres. Drug Des Devel
Ther 2:39–47.
54. Shi S, Hickey AJ. 2010. PLGA microparticles in respirable sizes
enhance an in vitro T cell response to recombinant Mycobacterium
tuberculosis antigen TB10.4-Ag85B. Pharm Res 27(2):350–360.
55. Mohajel N, Najafabadi AR, Azadmanesh K, Vatanara A, Moazeni
E, Rahimi A, Gilani K. 2012. Optimization of a spray drying process to
prepare dry powder microparticles containing plasmid nanocomplex.
Int J Pharm 423(2):577–585.
56. Billon A, Bataille B, Cassanas G, Jacob M. 2000. Development of
spray-dried acetaminophenmicroparticles using experimental designs.
Int J Pharm 203(1–2):159–168.
57. Baras B, Benoit MA, Gillard J. 2000. Parameters influencing the
antigen release from spray-dried poly(DL-lactide) microparticles. Int J
Pharm 200(1):133–145.
58. Anish C, Upadhyay AK, Sehgal D, Panda AK. 2014. Influences of
process and formulation parameters on powder flow properties and im-
munogenicity of spray dried polymer particles entrapping recombinant
pneumococcal surface protein A. Int J Pharm 466(1–2):198–210.
59. Bhardwaj V, Ankola DD, Gupta SC, Schneider M, Lehr CM, Ku-
marMN. 2009. PLGA nanoparticles stabilized with cationic surfactant:
Safety studies and application in oral delivery of paclitaxel to treat
chemical-induced breast cancer in rat. Pharm Res 26(11):2495–2503.
ALFAGIH ET AL., JOURNAL OF PHARMACEUTICAL SCIENCES DOI 10.1002/jps.24681
Q1 AU: Please check the hierarchy of all section headings for correctness.
Q2 AU: Please give the following address information for the manufacturers BDH, Laboratory Supplies, Sigma–Aldrich, Gibco by Life Tech-
nologies, Fisher Scientific, Geneflow Limited, Biosera, American Type Culture Collection (ATCC), Invitrogen, Ltd., Minitab Inc., SIGMA
Laborzentrifugen GmbH, Buchi Labortechnik, Malvern Instruments Ltd., Teva Pharma, Bio-Rad, Jasco, Epoch, BioTek Instruments Ltd.
and Carl Zeiss: town, state (if applicable) and country.
Q3 AU: As the first section is Introduction and it has no subparts, kindly check and correct the citation of ’section 1.5.1’ and replace it with full
name of the section.
Q4 AU: 13,000 rpm: please replace this with the correct g value.
Q5 AU: Please check the section heading Conclusions for correctness.
Q6 AU: Please provide publisher location in Ref. 28.
